Virus therapy plus immunotherapy before surgery for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of a cancer-killing virus (oncolytic virotherapy) and an immunotherapy drug (pembrolizumab) given before surgery for a certain type of rectal cancer. It aims to see if this approach helps shrink the tumor and improve outcomes for patients whose tumors have a normal DNA repair system (pMMR).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary, localized rectal cancer that has not spread far (stages cT2N0M0 to cT3bN2M0).
- Your tumor testing shows it has a normal DNA repair system (called pMMR or proficient mismatch repair).
- You are healthy enough for surgery that could cure the cancer, and you don't need other treatments before surgery.
- You have not had immunotherapy in the last 3 months, and you do not have a condition that weakens your immune system (like HIV, an autoimmune disease, or taking high-dose steroids).
- You are over 18, have good kidney and liver function, and are willing to use effective birth control during and for 4 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for locally advanced rectal cancer that combines chemotherapy and radiation with an immunotherapy drug (PD-1 inhibitor) before surgery. The goal is to shrink the tumor and improve the chance of successful surgery and long-term control.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial tests a combination of radiation, two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (regorafenib), and chemotherapy (CAPOX) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for people whose tumors have normal mismatch repair proteins (pMMR/MSS).
This study tests a combination of chemotherapy, radiation, and an immunotherapy drug (called anti-PD-1) before surgery for rectal cancer that has not spread. The goal is to see if this approach can shrink or eliminate the tumor, potentially improving outcomes.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.